The quantity and quality of worldwide new drug introductions, 1982-2003

Health Affairs
Henry G Grabowski, Y Richard Wang

Abstract

We examined trends in the introduction of new chemical entities (NCEs) worldwide from 1982 through 2003. Although annual introductions of NCEs decreased over time, introductions of high-quality NCEs (that is, global and first-in-class NCEs) increased moderately. Both biotech and orphan products enjoyed tremendous growth, especially for cancer treatment. Country-level analyses for 1993-2003 indicate that U.S. firms overtook their European counterparts in innovative performance or the introduction of first-in-class, biotech, and orphan products. The United States also became the leading market for first launch.

References

Feb 28, 2003·Journal of Health Economics·Joseph A DiMasiHenry G Grabowski
Jun 8, 2004·The Journal of Economic Perspectives : a Journal of the American Economic Association·Ernst R Berndt
Nov 24, 2004·Journal of Health Economics·Mary K Olson
Jul 30, 2005·Nature Reviews. Drug Discovery·Ernst R BerndtMatthew W Strobeck

❮ Previous
Next ❯

Citations

Jun 28, 2011·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Fernando AntoñanzasRoberto Rodríguez-Ibeas
Sep 11, 2012·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Saradindu Bhaduri, Thomas Brenner
May 13, 2008·Nature Reviews. Drug Discovery·Henry Grabowski
Jun 2, 2011·Nature Reviews. Drug Discovery·Fabio PammolliMassimo Riccaboni
Jan 17, 2007·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Juan del Llano
Jul 25, 2009·Wiener klinische Wochenschrift·Doris TschabitscherMarcus Müllner
Nov 1, 2007·Expert Opinion on Investigational Drugs·Susanne D Collins
Feb 20, 2008·FEBS Letters·Tony Pawson, Rune Linding
Apr 25, 2012·Journal of Health Economics·Ya-Ming LiuChee-Ruey Hsieh
Feb 22, 2011·Social Science & Medicine·Ya-Ming LiuChee-Ruey Hsieh
Apr 28, 2009·Clinical Therapeutics·Jaana E Martikainen, Hannes Enlund
Jul 26, 2015·Health Economics Review·Stephan Eger, Jörg C Mahlich
Jun 28, 2016·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Fernando GascónDavid de la Fuente
Jan 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joseph A DiMasi, Henry G Grabowski
Mar 9, 2006·Health Affairs·David B RidleyKevin A Schulman
Aug 27, 2009·Health Affairs·Donald W Light
Feb 10, 2018·The International Journal of Health Planning and Management·Tomas Gabriel Bas, Carolina Alejandra Oliu
Jun 18, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Fernando AntoñanzasCarmelo A Juárez-Castelló
Jun 1, 2013·Clinical Pharmacology and Therapeutics·A S KesselheimJ Avorn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

Related Papers

The Journal of Economic Perspectives : a Journal of the American Economic Association
Ernst R Berndt
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Joseph A DiMasi, Henry G Grabowski
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
James M HoffmanKarrie M Hontz
© 2021 Meta ULC. All rights reserved